Clinical Trials on Carcinoma, Small-Cell Lung

Total 14364 results

Syndax Pharmaceuticals

Completed

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Lung Cancer, Nonsmall Cell

United States
Jules Bordet Institute

Completed

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (PRECISION-F)

Metastatic Melanoma | Colorectal Cancer Metastatic | Metastatic Non-Small Cell Lung Carcinoma

Belgium
Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Ernesto Maranzano,MD; Fabio Trippa,MD

Completed

Stereotactic Ablative Radiotherapy in Locally Advanced Non Small Cell Lung Cancer (START-NEW-ERA)

Locally Advanced Lung Non-Small Cell Carcinoma

Italy
University Hospital, Antwerp
Universiteit Antwerpen; Belgian Cancer Registry

Enrolling by invitation

Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan (ZORALCS)

Smoking Cessation | Lung Cancer | Lung Cancer, Nonsmall Cell | Lung Cancer, Small Cell

Belgium
Shanghai Chest Hospital

Unknown

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Carcinoma | Non-small Cell Lung Cancer
City of Hope Medical Center
Addario Lung Cancer Medical Institute

Withdrawn

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Carcinoma

United States
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Ludwig Institute for Cancer Research
Xcovery Holding Company, LLC; Cancer Research Institute, New York City; MedImmune...

Completed

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Carcinoma | NSCLC | Non-small Cell Lung Cancer

United States
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Peking University People's Hospital
San Valley Biotechnology Incorporated

Unknown

Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients

Carcinoma | Lung Neoplasms | Non-small-cell Lung Cancer

China
Peking University People's Hospital
San Valley Biotechnology Incorporated

Unknown

Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

Carcinoma | Lung Neoplasms | Non-small-cell Lung Cancer

China
AstraZeneca

Completed

Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer (CANTABRICO)

Small Cell Lung Carcinoma Extensive Disease

Spain
Juravinski Cancer Center

Unknown

Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection (LINNEARRE-I)

Carcinoma | Non-Small-Cell Lung Cancer

Canada
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Large Cell Lung Carcinoma | Bronchioloalveolar Lung Carcinoma

United States
Gene Solutions

Recruiting

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

Non Small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage IIIC Non-Small Cell Lung Cancer | Tyrosine Kinase Inhibitors

Vietnam
University of Washington
National Cancer Institute (NCI)

Terminated

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Joseph J. Cullen, MD, FACS
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Recruiting

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (XACT-LUNG)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | NSCLC | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma

United States
Western Regional Medical Center

Terminated

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

United States
NewLink Genetics Corporation
National Cancer Institute (NCI)

Completed

Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Adenocarcinoma of Lung | Non-small Cell Carcinoma | Squamous Cell Carcinoma | Large Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung Carcinoma

United States
Fundación GECP

Recruiting

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Carcinoma Bronchiogenic Stage III

Spain
Stanford University
The American Association of Physicists in Medicine

Terminated

Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors

Pancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...

United States
AHS Cancer Control Alberta
Cross Cancer Institute

Completed

Hypofractionated Radiotherapy for Small Cell Lung Cancer

Small Cell Carcinoma | Lung Neoplasm

Canada
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
University Hospital, Rouen

Completed

Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery (PREOTEST)

Resectable Lung Non-Small Cell Carcinoma | Lung Neoplasm Malignant

France
Incyte Corporation

Terminated

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
Incyte Corporation

Terminated

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
Juan LI, MD

Recruiting

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non Small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

China
University of Miami

Completed

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Lung Cancer | Non Small Cell Lung Carcinoma | Hypermethylation

United States
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
NRG Oncology
National Cancer Institute (NCI); Radiation Therapy Oncology Group

Active, not recruiting

Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Carcinoma | Limited Stage Small Cell Lung Carcinoma

United States, Canada
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
NRG Oncology
Pennsylvania Department of Health Commonwealth Universal Research Enhancement...

Recruiting

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Hunan Province Tumor Hospital

Completed

Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

China
Eli Lilly and Company

Completed

A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Metastatic | Nonsquamous Non-Small Cell Neoplasm of Lung | Non-Small Cell Lung Cancer Stage IIIB

United Kingdom, Sweden
Li Zhang, MD

Not yet recruiting

Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations (TOP)

Non-small Cell Carcinoma | EGFR Gene Mutation

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
National Cancer Center, Korea
Merck Sharp & Dohme LLC

Unknown

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

Non-Small-Cell Lung Carcinoma

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Active, not recruiting

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

SCLC | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage

United States
Amgen

Not yet recruiting

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Small-Cell Lung Cancer | Extensive-Stage Small-Cell Lung Cancer
University of California, Davis
National Cancer Institute (NCI)

Recruiting

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE) (OBLITERATE)

Oligoprogressive | Non-small Cell Lung Cancer | Small-cell Lung Cancer

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Recruiting

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer (SORT)

Non Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States, Canada
University of Chicago

Recruiting

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Lung Cancer | Small-cell Lung Cancer | Extensive-stage Small-cell Lung Cancer

United States
Bristol-Myers Squibb

Completed

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer NSCLC | Small Cell Lung Cancer SCLC

China
GlaxoSmithKline

Completed

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell | Non-Small-Cell Lung Cancer

United States, Canada, Poland

Clinical Trials on Carcinoma, Small-Cell Lung

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations